Maine Physician Assistant Banned from Prescribing Drugs
Published Date: 3/20/2025
Notice
Summary
Rachel Jackson, a medical professional from Maine, lost her DEA registration because she no longer has the state authority to handle controlled substances. She didn’t ask for a hearing to challenge this, so the DEA officially revoked her registration, which expired at the end of 2024. This means she can’t legally prescribe or manage controlled drugs anymore, effective immediately.
Analyzed Economic Effects
4 provisions identified: 0 benefits, 4 costs, 0 mixed.
No State License = No DEA Registration
If a practitioner is not authorized by their State to handle controlled substances, they are not eligible to keep a DEA registration. The DEA applied this rule here after finding Rachel Jackson voluntarily surrendered her Maine physician assistant license effective July 11, 2023.
Not Requesting a Hearing Risks Default
If a registrant does not file a written request for a hearing after receiving an Order to Show Cause, they are deemed in default and the factual allegations are admitted. The DEA may then seek final agency action and enter a default final order.
Order Revokes MG5136723; Denies Renewals
The DEA revoked Rachel Jackson's Certificate of Registration No. MG5136723 and denied any pending applications to renew, modify, or obtain additional registration in Maine. The Order is effective April 21, 2025.
DEA Can Proceed Even If Registration Expired
The DEA retains authority to adjudicate an Order to Show Cause even if a registrant's DEA registration expired during the proceeding. In this case, the Agency noted the registration expired on December 31, 2024 but continued to final action.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
Previous / Next Documents
Previous: 2025-04750 — Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting
The Eunice Kennedy Shriver National Institute of Child Health & Human Development is holding a closed virtual meeting on April 30, 2025, to review grant applications focused on small business gynecological health projects. This meeting affects researchers and small businesses seeking funding, ensuring their private information stays safe. No direct money changes are announced, but the grant review could lead to new funding decisions soon.
Next: 2025-04753 — William Needham, N.P.; Decision and Order
William Needham, a nurse practitioner from Mississippi, lost his DEA registration because he no longer has the state authority to handle controlled substances. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately, with no money penalties mentioned.